Platinum Open Access Journal (ISSN: 2069-5837)

https://doi.org/10.33263/BRIAC126.80358041

New Diterpenoids of *Sigesbeckia pubescens* (Makino) Makino

Aleksey V. Myagchilov ^{1,2,*} , Larisa I. Sokolova ¹, Peter G. Gorovoy ²¹

- ¹ School of Natural Sciences, Far Eastern Federal University, 10 Ajax Bay, Russky Island, Vladivostok, Russia; *dfdfdf47@yandex.ru* (A.V.M.); *lisokolova@bk.ru* (L.I.S.);
- ² G. B. Elyakov Pacific Institute of Bioorganic Chemistry, Far Eastern Branch, Russian Academy of Science, 100 let Vladivostoku Prosp. 159, Vladivostok, Russia; petrgorovoy@gmail.com (P.G.G.);
- * Correspondence: dfdfdf47@yandex.ru (A.V.M.);

Scopus Author ID 57194203891

Received: 14.10.2021; Revised: 20.11.2021; Accepted: 24.11.2021; Published: 5.12.2021

Abstract: The composition of diterpenoids isolated from the aerial parts of *Sigesbeckia pubescens* growing in Primorsky Territory was investigated. Diterpenoids β -glucopyranosyl-18-acetoxy-16 α , 17-dihydroxykauran-19-oate (1), 15-*O*-malonylkirenol (2), and 16-*O*-malonylkirenol (3) were isolated by extraction and preparative column chromatography. The diterpenoids 1-3 were new compounds, the structures of which were established using NMR spectroscopy and mass spectrometry.

Keywords: Sigesbeckia pubescens; diterpenoids; NMR spectroscopy.

© 2021 by the authors. This article is an open-access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).

1. Introduction

Sigesbeckia pubescens (Makino) Makino – an annual plant of the Asteraceae family (Compositae), is widespread on the territory of China, Korea, Japan, and the Primorsky Region of the Russian Far East. An annual plant *Sigesbeckia pubescens* is used in traditional Chinese medicine to treat rheumatic arthritis, hypertension, malaria, and neurasthenia [1-4]. This plant has anti-inflammatory, anti-allergic, antithrombotic, antirheumatic, antihistamine, and anti-atherosclerotic properties [5-14]. The medicinal properties of *Sigesbeckia pubescens* are due to the presence in its composition of flavonoids, sesquiterpenoids, triterpenoids, and diterpenoids [5,7,15-19]. Pharmacological studies of this plant have shown that diterpenoids are the main biologically active compounds used to treat rheumatic arthritis [1]. It is necessary to conduct further studies of the composition of new diterpenoid compounds of this plant for further investigation of the pharmacological properties of *Sigesbeckia pubescens*.

2. Materials and Methods

2.1. General experimental procedures.

Mass spectrometric analysis used a Bruker MaXis (USA) with electrospray ionization (ESI) in positive-ion mode. NMR spectra were recorded in DMSO- d_6 on a Bruker AVANCE-400 spectrometer (USA) at an operating frequency 400 MHz.

2.2. Plant material.

The aerial parts of *Sigesbeckia pubescens* were collected in Primorsky Territory (in the vicinity of Shkotovo village, Shkotovo District, September 2020, during flowering) and identified by professor Peter G. Gorovoy (G. B. Elyakov Pacific Institute of Bioorganic Chemistry FEB RAS). A voucher specimen (№ 103618) was deposited in the Pacific Institute of Bioorganic Chemistry FEB RAS.

2.3. Extraction and isolation

The aerial parts of *Sigesbeckia pubescens* (100 g) were extracted with refluxing EtOH (70 %, 1000 ml) on a boiling-water bath for 1.5 h. The resulting extract was concentrated in a rotary evaporator to an aqueous residue that was worked up successively with CCl₄, EtOAc, and *n*-BuOH.

The BuOH extract was dried over Na₂SO₄, filtered, and evaporated to dryness at reduced pressure. The dry residue (15 g) was treated with EtOH (96%, 10 ml) and mixed with silica gel (5g, 70-230 mesh fraction). The mixture of extract and silica gel was dried at room temperature, transferred to a column (1×15 cm) of silica gel (70-230 mesh), and eluted with CCl₄ – EtOH (EtOH content increasing from 0 to 100 %). As a result of the BuOH extract of *Sigesbeckia pubescens* identified the compounds **1** (12 mg), **2** (35 mg), and **3** (28 mg).

 β -glucopyranosyl-18-acetoxy-16 α ,17-dihydroxykauran-19-oate (1)

HR-ESI-MS m/z: 579.2807 [M+Na]⁺ (calcd. for C₂₈H₄₄O₁₁Na⁺, 579.2776); ¹H NMR and ¹³C NMR: Table 1.

15-O-malonylkirenol (2)

HR-ESI-MS m/z: 447.5169 [M+Na]⁺ (calcd. for C₂₃H₃₆O₇Na⁺, 447.5175); ¹H NMR and ¹³C NMR: Table 1.

16-O-malonylkirenol (3)

HR-ESI-MS m/z: 447.5170 [M+Na]⁺ (calcd. for C₂₃H₃₆O₇Na⁺, 447.5175); ¹H NMR and ¹³C NMR: Table 1.

3. Results and Discussion

Preparative column chromatography on the butanol extract of *Sigesbeckia pubescens* afforded the three new diterpenoids (Figure 1).





3

Figure 1. Chemical structures of diterpenoids 1-3.

Table 1. ¹H and ¹³C NMR data of 1 - 3 in d⁶-DMSO (δ in ppm, J/Hz).

N⁰		${}^{1}\mathbf{H}$	¹³ C	№		${}^{1}\mathbf{H}$	¹³ C	N⁰		$^{1}\mathrm{H}$	¹³ C
		1				2				3	
1	а	0.68(m)	40.1	1	а	0.84(m)	48.6	1	а	0.86(m)	48.7
	b	1.71(m)			b	1.78(m)			b	1.78(m)	
2	а	1.35(m)	18.4	2		3.55(m)	62.9	2		3.56(m)	63.0
	b	1.83(m)									
3	а	1.04(m)	32.5	3	а	0.69(m)	44.8	3	а	0.69(m)	45.0
	b	2.17(m)			b	2.04(m)			b	2.04(m)	
4		-	47.7	4		-	40.3	4		-	40.3
5		1.25(m)	51.3	5		1.07(m)	55.0	5		1.07(m)	55.1
6	а	1.55(m)	21.8	6	а	1.20(m)	22.3	6	а	1.19(m)	22.3
	b	1.77(m)			b	1.58(m)		_	b	1.59(m)	
7	a	1.30(m)	41.9	7	a	1.90(m)	36.2	7	a	1.90(m)	36.3
	b	1.43(m)	110	0	b	2.22(m)	100.0	0	b	2.20(m)	120.2
8		-	44.2	8		-	139.2	8		-	138.3
9		0.92(m)	55.8	9		1.69(m)	50.6	9		1.69(m)	50.9
10	_	-	39.4	10	_	-	39.4	10	_	-	39.4
11	a h	1.4/(m) 1.70(m)	18.0	11	a h	1.41(m) 1.41(m)	18.0	11	a h	1.41(m) 1.41(m)	18.0
12	0	1.79(m) 1.26(m)	26.2	12	0	1.41(m)	22.2	12	0	1.41(m)	22.1
14	a b	1.20(III) 1.46(m)	20.2	14	a b	1.01(m)	32.3	14	a h	1.00(m)	32.1
13	U	1.40(m) 1.82(m)	44.9	13	U	1.91(III)	37.0	13	U	1.90(III)	37.6
14	а	1.02(m) 1.46(m)	37.0	14		5 13(s)	127.6	14		5 15(s)	128.8
17	b	1.71(m)	57.0	17		5.15(5)	127.0	17		5.15(5)	120.0
15	a	1.25(m)	53.1	15		4.84(dd.6.6.2.1)	79.1	15		3.51(m)	71.9
	b	1.39(m)									
16		-	81.0	16	а	3.44(m)	60.7	16	а	4.09(dd,8.8,2.2)	67.1
					b	3.56(m)			b	4.11(dd,8.8,2.1)	
17	а	3.38(m)	65.7	17		0.83(s,3H)	23.5	17		0.79(s,3H)	22.8
	b	3.46(d,11.6)									
18	а	3.82(d,10.4)	70.6	18		0.87(s,3H)	28.1	18		0.87(s,3H)	28.1
	b	4.26(d,10.4)									
19		-	173.4	19	а	3.11(d,10)	63.9	19	а	3.12(d,10)	63.9
					b	3.43(d,10)			b	3.44(d,10)	
20		0.84(s,3H)	15.6	20		0.72(s,3H)	16.7	20		0.67(s,3H)	16.8
1'		-	170.8	1'		-	167.3	1'		-	167.5
2'		1.94(s,3H)	20.9	2'		3.31(s,2H)	42.6	2'		3.31(s,2H)	42.2
1''		5.29(d,8.2)	94.5	3'		-	168.7	3'		-	168.5
2''		3.11(m)	72.9								
3''		3.15(m)	77.2								
4''		3.10(m)	70.1								<u> </u>
5''		3.21(m)	78.1								
6''	a	3.40(m)	61.2								
	b	3.61(d,10.4)									

3.1. Compound 1.

The molecular formula was identified as $C_{28}H_{44}O_{11}$ by HR-ESI-MS data ([M+Na]⁺ m/z 579.2807, calcd. 579.2776).

The ¹H NMR spectrum (Table 1) displayed signals for an anomeric proton at $\delta_{\rm H}$ 5.29 (d, H-1", J=8.2 Hz), two methyl groups at $\delta_{\rm H}$ 0.84 (s, CH₃-20), 1.94 (s, CH₃-2'). The ¹³C NMR spectrum revealed two methyls, twelve methylenes (three oxygenated, at $\delta_C 65.7$ and 70.6 in the aglycone, one oxygenated carbon in a sugar moiety at $\delta_{\rm C}$ 61.2), eight methines, and six quaternary carbons (two carbonyl carbon at $\delta_{\rm C}$ 170.8 and 173.4). The HMBC correlations from CH₃-20 to C-1, C-6, and C-10; from CH₂-17 to C-16; from CH₂-18 to C-3, C-4, and C-19, as depicted in Figure 2. The relative configuration has established the correlations in the NOESY spectrum of CH₂-18/H-5/H-9 and CH₂-17/H-9 (Figure 2). The NMR spectra of **1** were similar to those of 16α , 17, 18-trihydroxykauran-19-oic acid [20] except for an additional acetyl moiety $[\delta_H 1.94 (3H, s); \delta_C 170.8, 20.9]$ and glucopyranosyl moiety ($\delta_C 72.9, 77.2, 70.1, 78.1$, and 61.2). The acetyl group was attached to C-18, as was supported by an HMBC cross-peaks between H₂-18 ($\delta_{\rm H}$ 3.82 and 4.26) and the carboxyl carbon (173.4). The coupling constant of the anomeric proton at δ_H 5.29 (d, J=8.2 Hz) and C-1" signal at δ_C 94.5 indicated a β glucopyranose. In the HMBC spectrum (Figure 2), the correlation between the anomeric proton H-1" ($\delta_{\rm H}$ 5.29) and C-19 ($\delta_{\rm C}$ 173.4) showed that sugar moiety in diterpenoid was located at C-19. Therefore, the structure of compound **3** was defined as β -glucopyranosyl-18-acetoxy- 16α , 17-dihydroxykauran-19-oate.



Figure 2. Key HMBC and NOESY correlations of compound 1.

3.2. Compound 2.

The molecular formula was identified as $C_{23}H_{36}O_7$ by HR-ESI-MS ([M+Na]⁺ m/z 447.5169, calcd. 447.5175).

The ¹H NMR spectrum (Table 1) displayed signals for an olefinic proton at $\delta_{\rm H}$ 5.13 (s, 14-H), three methyl groups at $\delta_{\rm H}$ 0.83 (s, CH₃-17), 0.87 (s, CH₃-18) and 0.72 (s, CH₃-20). The ¹³C NMR spectrum revealed three methyls, nine methylenes, four methines (including one olefinic carbon at $\delta_{\rm c}$ 127.6), and four quaternary carbons (including one olefinic carbon at $\delta_{\rm c}$ 127.6), and four quaternary carbons (including one olefinic carbon at $\delta_{\rm c}$ 139.2). The HMBC correlations from CH₃-17 to C-12, C-13, and C-15; from CH₃-18 to C-3, C-4, and C-5; from CH₃-20 to C-1, C-5, C-9, and C-10; from H-14 to C-12 and C-13, as depicted in Figure 3. The relative configuration has established the correlations in the NOESY spectrum of CH₃-18/H-5/H-9, CH₃-17/H-9, and CH₃-20/H-2 (Figure 3). The NMR data were very similar to those of kirenol [21-23] except for a set of resonances due to a malonyl moiety [$\delta_{\rm H}$ 3.31 (2H, s); $\delta_{\rm c}$ 167.3, 168.7, 42.3]. Availability of correlation between H-15 ($\delta_{\rm H}$ 4.84) and C-1' ($\delta_{\rm c}$ 167.3) in spectrum HMBC states that malonic acid moiety in diterpenoid is linked at C-15 (Figure 3). Alkaline hydrolysis of compound **2** (5 % KOH/CH₃OH, 100 °C, 60 min) https://biointerfaceresearch.com/

formed the kirenol, and spectrum ¹³C NMR displayed a diagnostic resonance at δ_c 76.4 (C-15) defined the configuration of kirenol as the *R*. There is an empirical data for the chemical shift of C-15 in *ent*-pimarane skeleton. The chemical shift of C-15 for *R*-configuration is 77 ppm, while a change to 79 ppm for *S*-configuration [21,24,25]. Thus, the structure of compound **2** was determined to be 15*R*-malonyl-2 α ,16,19-trihydroxypimar-8(14)ene (15-*O*-malonylkirenol).



Figure 3. Key HMBC and NOESY correlations of compound 2.

3.3. Compound 3.

The molecular formula was established as $C_{23}H_{36}O_7$ by HR-ESI-MS data ([M+Na]⁺ m/z 447.5170, calcd. 447.5175).

The ¹H and ¹³C NMR spectra of compound **3** were nearly superimposable with those of compound **2** revealed a downfield shift of the signal of C-16 (+4.6 ppm) and upfield shift of the signals of C-15 (-7.2 ppm), showing that OH group has been attached to C-16 in diterpenoid by malonic acid [$\delta_{\rm H}$ 3.31 (s, 2H); $\delta_{\rm c}$ 167.5, 168.5, 42.2]. It was also supported by an HMBC cross-peak between the H₂-16 ($\delta_{\rm H}$ 4.09 and 4.11) and the carbonyl carbon ($\delta_{\rm C}$ 167.5). Alkaline hydrolysis of compound **3** (5 % KOH/CH₃OH, 100 °C, 60 min) formed the kirenol. Based on the empirical formula for 15,16-dihydroxy *ent*-pimarane skeletons [21,24,25], the chemical shift of C-15 in kirenol was 76.5 ppm. Therefore, the structure of compound **3** was defined as 16-malonyl-2 α ,15*R*,19-trihydroxypimar-8(14)ene (16-*O*-malonylkirenol).

Diterpenoids 1-3 were not previously described in the literature and were first isolated from *Sigesbeckia pubescens*.

4. Conclusions

Diterpenoids β -glucopyranosyl-18-acetoxy-16 α ,17-dihydroxykauran-19-oate (1), 15-*O*-malonylkirenol (2), and 16-*O*-malonylkirenol (3) were isolated for the first time from the aerial parts of *Sigesbeckia pubescens* by extraction and preparative column chromatography. The structures of the isolated compounds were elucidated and proved by NMR spectroscopy and mass spectrometry. The diterpenoids 1-3 were new and not previously described in the literature.

Funding

This research received no external funding.

Acknowledgments

This research has no acknowledgment.

Conflicts of Interest

The authors declared no potential conflict of interest.

References

- 1. Wang, R.; Chen, W.-H.; Shi, Y.-P. *ent*-Karane and *ent*-Pimarane Diterpenoids from *Siegesbeckia pubescens*. *J. Nat. Prod.* **2010**, *73*, 17-21, https://doi.org/10.1021/np9005579.
- Yuan, Q.-Q.; Song, W.-B.; Wang, W.-Q.; Wei, J.-J.; Li, J.; Liu, Y. New *ent*-Kaurane and *ent*-Pimarane diterpenoids from *Siegesbeckia pubescens*. *Phytochemistry Letters* 2017, 21, 273-277, https://doi.org/10.1016/j.phytol.2017.07.003.
- 3. Xiong, J.; Ma, Y.; Xu, Y. Diterpenoids from *Siegesbeckia pubescens*. Phytochemistry **1992**, *31*, 917-921, https://doi.org/10.1016/0031-9422(92)80039-H.
- Zhang, Q.R.; Zhong, Z.F.; Sang, W.; Xiong, W.; Tao, H.X.; Zhao, G.D.; Li, Z.X.; Tse, A.K.W; Hu, Y.J.; Yu, H. Comparative com-prehension on the antirheumatic Chinese herbal medicine *Siegesbeckiae* Herba: combined computational predictions and experimental investigations. *J. Ethnopharmacol.* 2019, 228, 200– 209, https://doi.org/10.1016/j.jep.2018.09.023.
- Tao, H.X.; Zhao, G.D.; Linghu, K.G.; Xiong, W.; Sang, W.; Wang, Y.; Yu, H. Botany, traditional use, phytochemistry, pharmacology and toxicology of *Sigesbeckie* Herba (Xixiancao): a review. *Phytochem. Rev.* 2020, https://doi.org/10.1007/s11101-020-09714-4.
- Linghu, K.G.; Zhao, G.D.; Xiong, W.; Sang, W.; Xiong, S.H.; Tse, A.K.W.; Hu, Y.; Bian, Z.; Wang, Y.; Yu, H. Comprehensive comparison on the anti-inflammatory effects of three species of *Sigesbeckia* plants based on NF-κB and MAPKs signal pathways in vitro. *J. Ethnopharmacol.* **2020**, *250*, 112530, https://doi.org/10.1016/j.jep.2019.112530.
- Wang, Q.; Liang, Y.-Y.; Li, K.-W.; Li, Y.; Niu, F.-J.; Zhou, S.-J.; Wei, H.-C.; Zhou, C.-Z. Herba Siegesbeckiae: A review on its traditional uses, chemical, constituents, pharmacological activities and clinical studies. J. Ethnopharmacol. 2021, 275, 114117, https://doi.org/10.1016/j.jep.2021.114117.
- Quan, P.; Jiao, B.; Shang, R.; Liu, C.; Fang, L. Alternative therapy of rheumatoid arthritis with a novel transdermal patch containing *Siegesbeckiae* Herba extract. *J. Ethnopharmacol.* 2021, 265, 113294, https://doi.org/10.106/j.jep.2020.113294.
- Wu, J.Y.; Chan, Y.C.; Guo, H.; Chen, Y.J.; Liu, Y.X.; Yi, H.; Yu, Z.L. Twenty-four- week oral dosing toxicities of Herba *Siegesbeckiae* in rats. *BMC Complement Med. Ther.* 2020, 20, 341, https://10.1186/s12906-020-03137-6.
- Sun, Z.; Zhang, Y.; Zhou, H.; Xu, J.; Gu, Q. Diverse diterpenoids and sesquiterpenoids from *Siegesbeckia pubescens* and their activity against RANKL-induced osteoclastogenesis. *Bioorganic Chemistry* 2021, 107, 104537, https://doi.org/10.1016/j.bioorg.2020.104537.
- 11. Xu, F.; Hu, H.; Li, Y.; Ren, Y.; Zhao, H.; Huang, Q.; Wang, J. A. New *ent*-Pimarane-Type Diterpenoids Glycoside from *Siegesbeckia pubescens. Rec. Nat. Prod.* 2018, *12*, 493-497, https://doi.org/10.25135/rnp.44.17.11.186.
- Wang, J.; Xie, K.; Duan, H.; Wang, Y.; Ma, H.; Fu, H. Isolation and characterization of diterpene glycoside from *Siegesbeckia pubescens*. *Bioorganic&Medicinal Chemistry Letters* 2017, 27, 1815-1819, https://doi.org/10.1016/j.bmcl.2017.02.051.
- Li, Y.-S.; Zhang, J.; Tian, G.-H.; Shang, H.-C.; Tang, H.-B. Kirenol, darutoside and hesperidin contribute to the anti-inflammatory and analgesic activities of *Siegesbeckia pubescens* Makino by inhibiting COX-2 expression and inflammatory cell infiltration. *J. Ethnopharmacol.* 2021, 268,113547, https://doi.org/10.1016/j.jep.2020.113547.
- 14. Lin, Y.-Y.; Xia, H.; Xia, G.-Y.; Li, X.-Y.; Zhao, C.; Zhang, X.-T.; Lin, S.; Tian, G.-H. Effect of *Siegesbeckiae* Herba in treating chronic pain. *China J. Chin. Mater. Med.* **2020**, *45*, 1851-1858, https://doi.org/10.19540/j.cnki.cjcmm.20191016.501.

- 15. Sun, Z.; Zhang, Y.; Zhou, H.; Xu, J.; Gu, Q. Diverse diterpenoids and sesquiterpenoids from *Siegesbeckia pubescens* and their activity against RANKL-induced osteoclastogenesis. *Bioorg. Chem.* 2020, 10, 104537, https://doi.org/10.1016/j.bioorg.2020.104537.
- 16. Nam, J.H. Vasodilatation effect of kirenol isolated from *Sigesbeckia pubescens*. *Korean J. Polar. Res.* **2020**, 33, 467–475, https://10.7732/KJPR.2020.33.5.467.
- Ren, J.; Yang, M.; Chen, J.; Ma, S.; Wang, N. Anti-inflammatory and wound healing potential of kirenol in diabetic rats through the suppression of inflammatory markers and matrix metalloproteinase expressions. *Biomed. Pharmacother* **2020**, *129*, 110475, https://doi.org/10.1016/j.biopha.2020.110475.
- Liu, W.; Li, Y.; Li, C. Kirenol exhibits the protective role against N-Methyl-N-Nitrosourea-induced gastric cancer in rats *via* modulating the oxidative stress and inflammatory markers. *J. Environ. Pathol. Toxicol. Oncol.* 2020, 39,345-355, https://doi.org/10.1615/JEnvironPatholToxicoOncol.2020035475.
- 19. Teng, T.; Xu, S.; Chen, F.; Li, X.; Gao, L.; Ye, Y. Research Progress in Chemical Constituents and Pharmacological Activities of *Siegesbeckie* Herba. *Chin. J. Mod. Appl. Pharm.* **2015**, *32*, 250-260, https://doi.org/10.12677/TCM.2021.101002.
- 20. Gao, H.; Li, P.; Li, D.; Du, X. Studies on chemical constituents of *Siegesbeckia pubescens*. *Chinese traditional and Herbal drugs* **2002**, *6*, 495-496.
- 21. Wang, J.; Duan, H.Q.; Wang, Y.; Pan, B.; Gao, C.; Gai, C.; Wu, Q.; Fu, H. *Ent*-Strobane and *Ent*-Pimarane Diterpenoids from *Siegesbeckia pubescens*. *J. Nat. Prod.* **2017**, *80*, 19-29, https://doi.org/10.1021/acs.jnatprod.6b00150.
- 22. Shim, S.-Y.; Lee, Y.E., Lee, M. Antioxidant compounds, kirenol and methyl *ent*-16a,17-dihydroxy-kauran-19-oate Bioactivity-Guided isolated from *Siegesbeckia glabrescens* attenuates MITF-mediated melanogenesis via inhibition of intracellular ROS production. *Molecules* 2021, 26, 1940, https://doi.org/10.3390/MOLECULES26071940.
- Ibrahim, S.R.M.; Altyar, A.E.; Sindi, I.A.; El-Agamy, D.S.; Abdallah, H.M.; Mohamed, S.G.A.; Mohamed, G.A. Kirenol: A promising bioactive metabolite from *Siegesbeckia species*: A detailed review. *J. Ethnopharmacol.* 2021, 281, 114552, https://10.1016/j.jep.2021.114552.
- 24. Giang, P.M.; Son, P.T.; Otsuka, H. *ent*-pimarane-type diterpenoids from *Siegesbeckia orientalis* L. *Chem. Pharm. Bull.* **2005**, *53*, 232–234, https://doi.org/10.1248/cpb.53.232.
- 25. Gao, X.; Rong, Z.; Long, G.; Hu, G.; Yan, T.; Li, N.; Jia, J.; Wang, A. ent-Pimarane diterpenoids from Siegesbeckia glabrescens with anti-inflammatory activity. Bioorg. Chem. 2020, 99, 103854, https://doi.org/10.1016/j.bioorg.2020.103854.